Retrospective Study
Copyright ©The Author(s) 2018.
World J Gastroenterol. Feb 14, 2018; 24(6): 716-724
Published online Feb 14, 2018. doi: 10.3748/wjg.v24.i6.716
Table 2 Patient and procedure characteristics by study year: 2009 is prior to split dosing, and 2011 is after split dosing
Characteristic2009 (n = 1987)2011 (n = 2238)Total (n = 4225)P value1
Age, yr
≤ 551096 (55.2)1311 (58.6)2407< 0.001
55-65606 (30.5)674 (30.1)1,280
65-75233 (11.7)253 (11.3)486
≥ 7552 (2.6)0 (0)52
Female1099 (55.3)1182 (52.8)22810.100
Race/ethnicity
White or Hispanic1652 (83.1)1846 (82.5)3498< 0.001
Black131 (6.6)160 (7.1)291
Asian128 (6.4)129 (5.8)257
Other20 (1.0)100 (4.5)120
BMI (kg/m2), mean (SD)1871 (94.2)2213 (98.9)40840.610
Current narcotics2 use
Yes131 (6.6)163 (7.3)2940.360
No1856 (93.4)2066 (92.3)3922
Current TCA use
Yes47 (2.4)31 (1.4)780.020
No1940 (97.6)2198 (98.2)4138
Type II diabetes
Yes164 (8.3)201 (9.0)3650.400
No1823 (91.7)2037 (91.0)3860
Bowel preparation quality
Adequate or excellent592 (30.6)886 (39.6)1478< 0.001
Good1044 (54.0)1048 (46.9)2092
Fair209 (10.8)189 (8.5)398
Inadequate or poor89 (4.6)113 (5.1)202
Polyp presence
Yes745 (37.5)807 (36.1)15520.330
No1242 (62.5)1431 (63.9)2673
Preparation type
8L PEG5 (0.3)17 (0.8)22< 0.001
MiraLAX/Gatorade541 (28.3)1228 (57.1)1769
4L PEG, GoLYTELY, NuLYTELY, Colyte, TriLyte1015 (53.1)771 (35.9)1786
Half-Lytely,Osmoprep, Moviprep, and others352 (18.4)133 (6.2)485
Preparation type
MiraLAX/Gatorade541 (28.3)1228 (57.1)1769< 0.001
4L PEG, GoLYTELY, NuLYTELY, Colyte, TriLyte1015 (53.1)771 (35.9)1786
Half-Lytely, Osmoprep, Moviprep, and others357 (18.7)150 (7.0)507
GI fellow presence
Yes187 (9.4)303 (13.5)490< 0.001
No1800 (90.6)1935 (86.5)3735